Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.

BMC cancer - 3 Jul 2018

Amini-Adle M, Khanafer N, Le-Bouar M, Duru G, Dalle S, Thomas L

Abstract excerpt

BACKGROUND: Anti-PD-1 and BRAF-inhibitors (BRAFi) have been approved as first-line treatments in advanced melanoma. To date, no prospective data are available to give the best sequence of treatment. The objective of this study was to evaluate in real-life the efficacy of anti-PD-1 after BRAFi, ipilimumab, or chemotherapy failure. METHODS: This was a single institution cohort analysis in patients treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRAF gene
Share to Ipilimumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Programmed Cell Death 1 Receptor

Share to Proto-Oncogene Proteins B-raf

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 29970025
DOI: 10.1186/s12885-018-4618-9
PMCID: PMC6029356

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.PMID 29970025Read ↗

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.Semantic proximity Read ↗

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Which drug, and when, for patients with BRAF-mutant melanoma?Semantic proximity Read ↗

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.Semantic proximity Read ↗

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.Semantic proximity Read ↗

The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.Semantic proximity Read ↗

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read ↗

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma.Semantic proximity Read ↗

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Semantic proximity Read ↗

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.Semantic proximity Read ↗

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.Semantic proximity Read ↗

Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st-line BRAF-targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.